The nitric oxide pathway and possible therapeutic options in pre-eclampsia

British Journal of Clinical Pharmacology

Volumn 78, Issue 2, 2014, Pages 244-257

  Johal, Tamanrit ^a   Lees, Christoph C ^b,c   Everett, Thomas R ^a   Wilkinson, Ian B ^d  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

endothelial dysfunction; l arginine; organic nitrates; pre eclampsia; S nitrosoglutathione; sildenafil

Indexed keywords

ACETYLSALICYLIC ACID; ANTIOXIDANT; ARGININE; CYCLIC GMP; GLUTATHIONE; GLYCERYL TRINITRATE; ISOSORBIDE DINITRATE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; OXIDOREDUCTASE INHIBITOR; S NITROSOGLUTATHIONE; S NITROSOGLUTATHIONE REDUCTASE INHIBITOR; S NITROSOTHIOL; SILDENAFIL; UNCLASSIFIED DRUG; ALDEHYDE DEHYDROGENASE; FORMALDEHYDE DEHYDROGENASE, GLUTATHIONE-INDEPENDENT; PHOSPHODIESTERASE INHIBITOR; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONAMIDE;

ARTICLE; BIOAVAILABILITY; CLINICAL RESEARCH; DIET SUPPLEMENTATION; ENDOTHELIAL DYSFUNCTION; HUMAN; MATERNAL MORBIDITY; MATERNAL MORTALITY; NEWBORN MORBIDITY; NEWBORN MORTALITY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PREECLAMPSIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); VASCULAR ENDOTHELIUM; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; ENZYMOLOGY; FEMALE; METABOLISM; PRE-ECLAMPSIA; PREGNANCY;

ALDEHYDE OXIDOREDUCTASES; CLINICAL TRIALS AS TOPIC; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; ISOSORBIDE DINITRATE; NITRIC OXIDE; NITRIC OXIDE DONORS; NITROGLYCERIN; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PRE-ECLAMPSIA; PREGNANCY; PURINES; S-NITROSOTHIOLS; SILDENAFIL CITRATE; SULFONAMIDES;

EID: 84904618923     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12301     Document Type: Article

References (74)

1. Duley L,. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009; 33: 130-137.
2. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM,. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). (Review). Hypertens Pregnancy 2001; 20: 9-14.
3. Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF,. WHO analysis of causes of maternal death: a systematic review. Lancet 2006; 367: 1066-1074.
4. Moore T, Hennessy EM, Myles J, Johnson SJ, Draper ES, Costeloe KL, Marlow N,. Neurological and developmental outcome in extremely preterm children born in England in 1995 and 2006: the EPICure studies. BMJ 2012; 345: e7961.
5. Hintz SR, Kendrick DE, Wilson-Costello DE, Das A, Bell EF, Vohr BR, Higgins RD, NICHD Neonatal Research Network. Early-childhood neurodevelopmental outcomes are not improving for infants born at <25 weeks' gestational age. Pediatrics 2011; 127: 62-70.
6. Vohr BR, Wright LL, Dusick AM, Mele L, Verter J, Steichen JJ, Simon NP, Wilson DC, Broyles S, Bauer CR, Delaney-Black V, Yolton KA, Fleisher BE, Papile LA, Kaplan MD,. Neurodevelopmental and functional outcomes of extremely low birth weight infants in the National Institute of Child Health and Human Development Neonatal Research Network, 1993-1994. Pediatrics 2000; 105: 1216-1226.
7. Saigal S, Doyle LW,. An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet 2008; 371: 261-269. doi: 10.1016/S0140-6736(08)60136-1. Review.
8. Khong TY, De Wolf F, Robertson WB, Brosens I,. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol 1986; 93: 1049-1059.
9. Redman CW, Sargent IL,. Placental stress and pre-eclampsia: a revised view. Placenta 2009; 30: (Suppl A): S38-42.
10. Roberts JM, Gammill HS,. Preeclampsia: recent insights. Hypertension 2005; 46: 1243-1249.
11. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R,. Pre-eclampsia. Lancet 2010; 376: 631-644.
12. Crane MS, Rossi AG, Megson IL,. A potential role for extracellular nitric oxide generation in cGMP-independent inhibition of human platelet aggregation: biochemical and pharmacological considerations. Br J Pharmacol 2005; 144: 849-859.
13. Konijnenberg A, Stokkers EW, van der Post JA, Schaap MC, Boer K, Bleker OP, Sturk A,. Extensive platelet activation in preeclampsia compared with normal pregnancy: enhanced expression of cell adhesion molecules. Am J Obstet Gynecol 1997; 176: 461-469.
14. Jeremy JY, Rowe D, Emsley AM, Newby AC,. Nitric oxide and the proliferation of vascular smooth muscle cells. Cardiovasc Res 1999; 43: 580-594.
15. Gaboury JP, Niu XF, Kubes P,. Nitric oxide inhibits numerous features of mast cell-induced inflammation. Circulation 1996; 93: 318-326.
16. Zhang HH, Wang YP, Chen DB,. Analysis of nitroso-proteomes in normotensive and severe preeclamptic human placentas. Biol Reprod 2011; 84: 966-975.
17. Rani N, Dhingra R, Arya DS, Kalaivani M, Bhatla N, Kumar R,. Role of oxidative stress markers and antioxidants in the placenta of preeclamptic patients. J Obstet Gynaecol Res 2010; 36: 1189-1194.
18. Hsieh TT, Chen SF, Lo LM, Li MJ, Yeh YL, Hung TH,. The association between maternal oxidative stress at mid-gestation and subsequent pregnancy complications. Reprod Sci 2012; 19: 505-512.
19. Zhou A, Carrell RW, Murphy MP, Wei Z, Yan Y, Stanley PL, Stein PE, Broughton Pipkin F, Read RJ,. A redox switch in angiotensinogen modulates angiotensin release. Nature 2010; 468: 108-111.
20. Knapen MF, Mulder TP, Van Rooij IA, Peters WH, Steegers EA,. Low whole blood glutathione levels in pregnancies complicated by preeclampsia or the hemolysis, elevated liver enzymes, low platelets syndrome. Obstet Gynecol 1998; 92: 1012-1015.
21. Raijmakers MT, Zusterzeel PL, Steegers EA, Hectors MP, Demacker PN, Peters WH,. Plasma thiol status in preeclampsia. Obstet Gynecol 2000; 95: 180-184.
22. Sandrim VC, Palei AC, Metzger IF, Gomes VA, Cavalli RC, Tanus-Santos JE,. Nitric oxide formation is inversely related to serum levels of antiangiogenic factors soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia. Hypertension 2008; 52: 402-407.
23. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA,. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-683.
24. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA, CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355: 992-1005. Erratum in: N Engl J Med. 2006 Oct 26;355(17):1840.
25. Everett TR, Wilkinson IB, Lees CC,. Drug development in preeclampsia: a 'no go' area? J Matern Fetal Neonatal Med 2012; 25: 50-52.
26. Rumbold A, Duley L, Crowther CA, Haslam RR,. Antioxidants for preventing pre-eclampsia. Cochrane Database Syst Rev 2008; (1) CD004227. doi: 10.1002/14651858.CD004227.pub3. Review.
27. Chen Z, Zhang J, Stamler JS,. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci U S A 2002; 99: 8306-8311.
28. Ramsay B, De Belder A, Campbell S, Moncada S, Martin JF,. A nitric oxide donor improves uterine artery diastolic blood flow in normal early pregnancy and in women at high risk of pre-eclampsia. Eur J Clin Invest 1994; 24: 76-78.
29. Grunewald C, Kublickas M, Carlström K, Lunell NO, Nisell H,. Effects of nitroglycerin on the uterine and umbilical circulation in severe preeclampsia. Obstet Gynecol 1995; 86: 600-604.
30. Cetin A, Yurtcu N, Guvenal T, Imir AG, Duran B, Cetin M,. The effect of glyceryl trinitrate on hypertension in women with severe preeclampsia, HELLP syndrome, and eclampsia. Hypertens Pregnancy 2004; 23: 37-46.
31. Manzur-Verástegui S, Mandeville PB, Gordillo-Moscoso A, Hernández-Sierra JF, Rodríguez-Martínez M,. Efficacy of nitroglycerine infusion versus sublingual nifedipine in severe pre-eclampsia: a randomized, triple-blind, controlled trial. Clin Exp Pharmacol Physiol 2008; 35: 580-585.
32. Lees C, Valensise H, Black R, Harrington K, Byiers S, Romanini C, The CS,. efficacy and fetal-maternal cardiovascular effects of transdermal glyceryl trinitrate in the prophylaxis of pre-eclampsia and its complications: a randomized double-blind placebo-controlled trial. Ultrasound Obstet Gynecol 1998; 12: 334-338.
33. Picciolo C, Roncaglia N, Neri I, Pasta F, Arreghini A, Facchinetti F,. Nitric oxide in the prevention of pre-eclampsia. Prenat Neonatal Med 2000; 5: 212-215. [: CN-00399568].
34. Cacciatore B, Halmesmäki E, Kaaja R, Teramo K, Ylikorkala O,. Effects of transdermal nitroglycerin on impedance to flow in the uterine, umbilical, and fetal middle cerebral arteries in pregnancies complicated by preeclampsia and intrauterine growth retardation. Am J Obstet Gynecol 1998; 179: 140-145.
35. Trapani A Jr, Gonçalves LF, Pires MM,. Transdermal nitroglycerin in patients with severe pre-eclampsia with placental insufficiency: effect on uterine, umbilical and fetal middle cerebral artery resistance indices. Ultrasound Obstet Gynecol 2011; 38: 389-394.
36. Luzi G, Caserta G, Iammarino G, Clerici G, Di Renzo GC,. Nitric oxide donors in pregnancy: fetomaternal hemodynamic effects induced in mild pre-eclampsia and threatened preterm labor. Ultrasound Obstet Gynecol 1999; 14: 101-109.
37. Gori T, Parker JD,. Nitrate tolerance: a unifying hypothesis. Circulation 2002; 106: 2510-2513.
38. Miller MR, Megson IL,. Recent developments in nitric oxide donor drugs. Br J Pharmacol 2007; 151: 305-321. Review.
39. Bath PM, Pathansali R, Iddenden R, Bath FJ,. The effect of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure and platelet function in acute stroke. Cerebrovasc Dis 2001; 11: 265-272.
40. Davis DG, Brown PM,. Glyceryl trinitrate (GTN) patches are unsuitable in hypertensive pregnancy. Aust N Z J Obstet Gynaecol 2001; 41: 474.
41. Thaler I, Amit A, Kamil D, Itskovitz-Eldor J,. The effect of isosorbide dinitrate on placental blood flow and maternal blood pressure in women with pregnancy induced hypertension. Am J Hypertens 1999; 12: (4 Pt 1): 341-347.
42. Nakatsuka M, Takata M, Tada K, Asagiri K, Habara T, Noguchi S, Kudo T,. A long-term transdermal nitric oxide donor improves uteroplacental circulation in women with preeclampsia. J Ultrasound Med 2002; 21: 831-836.
43. Martínez-Abundis E, González-Ortiz M, Hernández- Salazar F, Huerta-J-Lucas MT,. Sublingual isosorbide dinitrate in the acute control of hypertension in patients with severe preeclampsia. Gynecol Obstet Invest 2000; 50: 39-42.
44. Thaler I, Amit A, Jakobi P, Itskovitz-Eldor J,. The effect of isosorbide dinitrate on uterine artery and umbilical artery flow velocity waveforms at mid-pregnancy. Obstet Gynecol 1996; 88: 838-843.
45. Makino Y, Izumi H, Makino I, Shirakawa K,. The effect of nitric oxide on uterine and umbilical artery flow velocity waveform in pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 1997; 73: 139-143.
46. Groten T, Fitzgerald J, Lehmann T, Schneider U, Kähler C, Schleussner E,. Reduction of preeclampsia related complications with the NO-donor penterythriltetranitrat (petn) in risk pregnancies-A prospective randomized double-blind placebo pilot study. Pregnancy Hypertens 2012; 2: 181.
47. Sayed N, Kim DD, Fioramonti X, Iwahashi T, Durán WN, Beuve A,. Nitroglycerin-induced S-nitrosylation and desensitization of soluble guanylyl cyclase contribute to nitrate tolerance. Circ Res 2008; 103: 606-614.
48. Zai A, Rudd MA, Scribner AW, Loscalzo J,. Cell-surface protein disulfide isomerase catalyzes transnitrosation and regulates intracellular transfer of nitric oxide. J Clin Invest 1999; 103: 393-399.
49. Bryan NS, Rassaf T, Maloney RE, Rodriguez CM, Saijo F, Rodriguez JR, Feelisch M,. Cellular targets and mechanisms of nitros(yl)ation: an insight into their nature and kinetics in vivo. Proc Natl Acad Sci U S A 2004; 101: 4308-4313.
50. de Belder AJ, MacAllister R, Radomski MW, Moncada S, Vallance PJ,. Effects of S-nitroso-glutathione in the human forearm circulation: evidence for selective inhibition of platelet activation. Cardiovasc Res 1994; 28: 691-694.
51. Ramsay B, Radomski M, De Belder A, Martin JF, Lopez-Jaramillo P,. Systemic effects of S-nitroso-glutathione in the human following intravenous infusion. Br J Clin Pharmacol 1995; 40: 101-102.
52. Langford EJ, Brown AS, Wainwright RJ, de Belder AJ, Thomas MR, Smith RE, Radomski MW, Martin JF, Moncada S,. Inhibition of platelet activity by S-nitrosoglutathione during coronary angioplasty. Lancet 1994; 344: 1458-1460.
53. Langford EJ, Wainwright RJ, Martin JF,. Platelet activation in acute myocardial infarction and unstable angina is inhibited by nitric oxide donors. Arterioscler Thromb Vasc Biol 1996; 16: 51-55.
54. de Belder A, Lees C, Martin J, Moncada S, Campbell S,. Treatment of HELLP syndrome with nitric oxide donor. Lancet 1995; 345: 124-125.
55. Lees C, Langford E, Brown AS, de Belder A, Pickles A, Martin JF, Campbell S,. The effects of S-nitrosoglutathione on platelet activation, hypertension, and uterine and fetal Doppler in severe preeclampsia. Obstet Gynecol 1996; 88: 14-19.
56. Hausvater A, Giannone T, Sandoval YH, Doonan RJ, Antonopoulos CN, Matsoukis IL, Petridou ET, Daskalopoulou SS,. The association between preeclampsia and arterial stiffness. J Hypertens 2012; 30: 17-33.
57. Martínez-Ruiz A, Lamas S,. Signalling by NO-induced protein S-nitrosylation and S-glutathionylation: convergences and divergences. Cardiovasc Res 2007; 75: 220-228.
58. Kaposzta Z, Baskerville PA, Madge D, Fraser S, Martin JF, Markus HS,. L-arginine and S-nitrosoglutathione reduce embolization in humans. Circulation 2001; 103: 2371-2375.
59. Kaposzta Z, Martin JF, Markus HS,. Switching off embolization from symptomatic carotid plaque using S-nitrosoglutathione. Circulation 2002; 105: 1480-1484.
60. Colagiovanni DB, Borkhataria D, Looker D, Schuler D, Bachmann C, Sagelsdorff P, Honarvar N, Rosenthal GJ,. Preclinical 28-day inhalation toxicity assessment of s-nitrosoglutathione in beagle dogs and Wistar rats. Int J Toxicol 2011; 30: 466-477.
61. Facchinetti F, Longo M, Piccinini F, Neri I, Volpe A,. L-arginine infusion reduces blood pressure in preeclamptic women through nitric oxide release. J Soc Gynecol Investig 1999; 6: 202-207.
62. Vadillo-Ortega F, Perichart-Perera O, Espino S, Avila-Vergara MA, Ibarra I, Ahued R, Godines M, Parry S, Macones G, Strauss JF,. Effect of supplementation during pregnancy with L-arginine and antioxidant vitamins in medical food on pre-eclampsia in high risk population: randomised controlled trial. BMJ 2011; 342: d2901.
63. Neri I, Monari F, Sgarbi L, Berardi A, Masellis G, Facchinetti F,. L-arginine supplementation in women with chronic hypertension: impact on blood pressure and maternal and neonatal complications. J Matern Fetal Neonatal Med 2010; 23: 1456-1460.
64. Samangaya RA, Mires G, Shennan A, Skillern L, Howe D, McLeod A, Baker PN,. A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia. Hypertens Pregnancy 2009; 28: 369-382.
65. Ramesar SV, Mackraj I, Gathiram P, Moodley J,. Sildenafil citrate decreases sFlt-1 and sEng in pregnant l-NAME treated Sprague-Dawley rats. Eur J Obstet Gynecol Reprod Biol 2011; 157: 136-140.
66. Herraiz S, Pellicer B, Serra V, Cauli O, Cortijo J, Felipo V, Pellicer A,. Sildenafil citrate improves perinatal outcome in fetuses from pre-eclamptic rats. BJOG 2012; 119: 1394-1402.
67. Stanley JL, Andersson IJ, Poudel R, Rueda-Clausen CF, Sibley CP, Davidge ST, Baker PN,. Sildenafil citrate rescues fetal growth in the catechol-O-methyl transferase knockout mouse model. Hypertension 2012; 59: 1021-1028.
68. Nassar AH, Masrouha KZ, Itani H, Nader KA, Usta IM,. Effects of sildenafil in Nω-nitro-L-arginine methyl ester-induced intrauterine growth restriction in a rat model. Am J Perinatol 2012; 29: 429-434.
69. Green LS, Chun LE, Patton AK, Sun X, Rosenthal GJ, Richards JP,. Mechanism of inhibition for N6022, a first-in-class drug targeting S-nitrosoglutathione reductase. Biochemistry 2012; 51: 2157-2168.
70. Chen Q, Sievers RE, Varga M, Kharait S, Haddad DJ, Patton AK, Delany CS, Mutka SC, Blonder JP, Dubé GP, Rosenthal GJ, Springer ML,. Pharmacological inhibition of S-nitrosoglutathione reductase improves endothelial vasodilatory function in rats in vivo. J Appl Physiol 2013; 114: 752-760.
71. Colagiovanni DB, Drolet DW, Langlois-Forget E, Piché MP, Looker D, Rosenthal GJ,. A nonclinical safety and pharmacokinetic evaluation of N6022: a first-in-class S-nitrosoglutathione reductase inhibitor for the treatment of asthma. Regul Toxicol Pharmacol 2012; 62: 115-124.
72. CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. Lancet 1994; 343: 619-629.
73. Momi S, Emerson M, Paul W, Leone M, Mezzasoma AM, Del Soldato P, Page CP, Gresele P,. Prevention of pulmonary thromboembolism by NCX 4016, a nitric oxide-releasing aspirin. Eur J Pharmacol 2000; 397: 177-185.
74. Chazov EI, Rodnenkov OV, Zorin AV, Lakomkin VL, Gramovich VV, Vyborov ON, Dragnev AG, Timoshin CA, Buryachkovskaya LI, Abramov AA, Massenko VP, Arzamastsev EV, Kapelko VI, Vanin AF,. Hypotensive effect of Oxacom® containing a dinitrosyl iron complex with glutathione: animal studies and clinical trials on healthy volunteers. Nitric Oxide 2012; 26: 148-156.